Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29814465 | 0.89 | MKNK1 (0.50) | ALOX5APFEN1AXLLRRK2USP30 | |
| SCHEMBL15334213 | 0.83 | LRRK2 (0.57) | ALOX5APFEN1AXLLRRK2MET | |
| SCHEMBL30388102 | 0.83 | LRRK2 (0.57) | ALOX5APFEN1AXLLRRK2MET | |
| SCHEMBL1814407 | 0.82 | LRRK2 (0.51) | ALOX5APFEN1AXLLRRK2SMARCA2 | |
| SCHEMBL17795258 | 0.82 | LRRK2 (0.51) | ALOX5APFEN1LRRK2USP30SMARCA2 | |
| SCHEMBL18183699 | 0.81 | AXL (0.50) | ALOX5APFEN1AXLLRRK2USP30 | |
| Ammonia Solution, Strong SCHEMBL28956665 | 0.81 | LRRK2 (0.50) | ALOX5APFEN1LRRK2USP30SMARCA2 | |
| SCHEMBL28956664 | 0.80 | ALOX5AP (0.48) | ALOX5APFEN1LRRK2USP30MET | |
| SCHEMBL29615362 | 0.80 | ALOX5AP (0.48) | ALOX5APFEN1LRRK2USP30MET | |
| SCHEMBL17785770 | 0.79 | AXL (0.51) | AXLLRRK2SMARCA2SMARCA4MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119370-A1 | BRD4-JAK2 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-04-21 | — | — | US | disclosed |
| US-8835482-B2 | Substituted indazole and aza-indazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835482-B2 | Substituted indazole and aza-indazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| WO-2010145883-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | ALOX5AP 472/4885FEN1 1081/4885AXL 4292/4885 |
| US-20220119370-A1 | BRD4-JAK2 INHIBITORS | BRD4, BICRA, JAK2 | ALOX5AP 3414/4885FEN1 4488/4885AXL 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.